

COVID-19 Vaccine Quick Facts

Revised 01/01/2021

	<u>Pfizer</u>	<u>Moderna</u>
Use	<ul style="list-style-type: none"> • 16 years of age and greater • No data on use with other vaccines • Post-vaccination protective measures are required (masking, distancing, hand/cough hygiene) as vaccine is not 100% effective and post-vaccine infection and transmission data is unknown. 	<ul style="list-style-type: none"> • 18 years of age and greater • No data on use with other vaccines • Post-vaccination protective measures are required (masking, distancing, hand/cough hygiene) as vaccine is not 100% effective and post-vaccine infection and transmission data is unknown.
Contraindications	Severe allergic reaction after a previous dose of this vaccine or to any ingredient in this vaccine. If pregnant or breastfeeding, consult PCP.	Severe allergic reaction after a previous dose of this vaccine or to any ingredient in this vaccine. If pregnant or breastfeeding, consult PCP.
Post-COVID Recommendation	May receive after isolation period is completed; discuss with PCP	
Doses Required	Two doses (0.3 mL IM); 21 days apart	Two doses (0.5 mL IM); 28 days apart
Immunity post-injection	52.4% efficacy after first dose	~80% efficacy 14 days after first dose
Effectiveness	95%, as soon as 7 days after second dose	94+%, as soon as 14 days after the second dose
Side effects	<p>Mild: Injection site (IS) pain [11.2%], fatigue [5.5%], HA [5.1%], muscle pain [2.4%], chills [5.3%], joint pain, fever [6.1%], IS swelling, IS redness, nausea [1.1%], malaise, swollen lymph nodes (lymphadenopathy) [0.3%]; contact PCP if indicated.</p> <p>Severe: Difficulty breathing, swelling of face and throat, rapid heartbeat, generalized body rash, dizziness, weakness; call 911 or go to hospital if indicated.</p>	<p>Mild: Injection site (IS) pain [4.1%], fatigue [9.7%], HA [4.5%], muscle pain [8.9%], chills, joint pain [5.2%], fever, IS swelling, IS redness [2%], IS hardness, nausea, vomiting, swollen lymph nodes (lymphadenopathy); contact PCP if indicated.</p> <p>Severe: Difficulty breathing, swelling of face and throat, rapid heartbeat, generalized body rash, dizziness, weakness; call 911 or go to hospital if indicated.</p>
Reporting of side effects	<p>Vaccine Adverse Event Reporting System (VAERS) using online or PDF form. VAERS can also be reached at (800) 822-7967. Also report side effects to Pfizer. The patient can also use the V-Safe app after vaccination for monitoring of side effects, text reminders for the second dose and telephone follow up with the CDC.</p>	<p>Vaccine Adverse Event Reporting System (VAERS) using online or PDF form. VAERS can also be reached at (866) 663-3762. Also report side effects to Moderna via email at ModernaPV@modernatx.com. The patient can also use the V-Safe app after vaccination for monitoring of side effects, text reminders for the second dose and telephone follow up with the CDC.</p>
Safety	No known concerns. FDA and CDC continue to monitor safety. The Countermeasures Injury Compensation Program (CICP) is a federal program that may assist in medical care expenses related to serious injury from this vaccine.	
Recording of vaccination data	Florida has an immunization information system titled Florida SHOTS . The site at which the vaccine is provided is most likely reporting the vaccination there. A hard copy of the vaccine administration record will also be provided at the time of vaccination.	
Approval	Emergency use authorization provided on 12/11/2020 . Clinical trial includes 43,931 enrollees (30% from U.S.), over 150 clinical sites and 39 U.S. states in a	Emergency use authorization provided on 12/17/2020 . Clinical trial includes 30,420 enrollees (100% from U.S.) over 89 clinical sites and 32 U.S. states in a randomized, 1:1, placebo-controlled trial.

	randomized, double-blind, 1:1, placebo-controlled trial.	
Mechanism of action	Contains messenger RNA (mRNA), which is genetic material. The vaccine contains a small piece of the SARS-CoV-2 virus’s mRNA that instructs cells in the body to make the virus’s distinctive “spike” protein. When a person receives this vaccine, their body produces copies of the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against SARS-CoV-2. The vaccine does not contain a live virus, nor enter the cell nucleus to alter DNA.	Contains messenger RNA (mRNA), which is genetic material. The vaccine contains a small piece of the SARS-CoV-2 virus’s mRNA that instructs cells in the body to make the virus’s distinctive “spike” protein. After a person receives this vaccine, their body produces copies of the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against SARS-CoV-2. The vaccine does not contain a live virus, nor enter the cell nucleus to alter DNA.
Storage	<ul style="list-style-type: none"> • Ultracold (-94F) freezer: up to 6 months • Refrigerator: up to 5 days • Room temp: 6 hours 	<ul style="list-style-type: none"> • Regular freezer: up to 6 months • Refrigerator: 7-30 days • Once opened: 6 hours
Dilution	Yes; dilute 5-dose vial with 1.8 mL 0.9% sodium chloride (do not use bacteriostatic NS). Required at point/site of dispensing	No

References:

United States Food & Drug Administration [FDA]. (2020). FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine. FDA. <https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19>

FDA. (2020). FDA takes additional action in fight against COVID-19 by issuing emergency use authorization for second COVID-19 vaccine. FDA. <https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid>

Pfizer. (2020). Pfizer-BioNTech COVID-19 vaccine U.S. distribution fact sheet. Pfizer. https://www.pfizer.com/news/hot-topics/covid_19_vaccine_u_s_distribution_fact_sheet